OCA
KRTX

Octagon Capital Advisors’s Karuna Therapeutics, Inc. Common Stock KRTX Stock Holding History

Octagon Capital Advisors’s Portfolio KRTX Stock Details KRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-34,500
Closed -$7.76M – 43
2022
Q3 		$7.76M Buy
+34,500
New +$6.98M 1.34% 18

Other funds holding KRTX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Octagon Capital Advisors's KRTX Position: Q4 2022 in Review

Octagon Capital Advisors sold out of Karuna Therapeutics, Inc. Common Stock (KRTX) in Q4 2022, closing a stake of 34,500 shares — an estimated $7.76M sold.

Octagon Capital Advisors first reported a position in KRTX in Q3 2022 and held it in 1 quarter. The position peaked at $7.76M in Q3 2022. 248 funds tracked by Wall St. Rank hold KRTX as of Q4 2022.

  • Octagon Capital Advisors reported no remaining Karuna Therapeutics, Inc. Common Stock position as of Q4 2022 after selling out during the quarter.
  • Octagon Capital Advisors sold 34,500 Karuna Therapeutics, Inc. Common Stock shares in Q4 2022, an estimated $7.76M.
  • Octagon Capital Advisors first reported a position in Karuna Therapeutics, Inc. Common Stock in Q3 2022 and held it in 1 quarter.
  • Octagon Capital Advisors's Karuna Therapeutics, Inc. Common Stock position peaked at $7.76M in Q3 2022.
  • 248 funds tracked by Wall St. Rank held Karuna Therapeutics, Inc. Common Stock as of Q4 2022.

Based on Octagon Capital Advisors's 13F filing for Q4 2022, filed 14 Feb 2023.